Matches in Nanopublications for { ?s ?p "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP314757.RASVyjgOYRbjOrK6wKdwDwIG79ALtVu3SpgGMrIzxIlx0130_assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP314757.RASVyjgOYRbjOrK6wKdwDwIG79ALtVu3SpgGMrIzxIlx0130_provenance.
- NP939435.RASVD72IHShS_socjxO67CYIgJVX8RGq6-jWIaGpeArSA130_assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP939435.RASVD72IHShS_socjxO67CYIgJVX8RGq6-jWIaGpeArSA130_provenance.
- NP314881.RAmkkK9x_G9ve-IGOvkCNhvsE3aTAJPgYlMukmiTiNAq4130_assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP314881.RAmkkK9x_G9ve-IGOvkCNhvsE3aTAJPgYlMukmiTiNAq4130_provenance.
- NP939433.RAmYGiDuBotZpQckKjVB7qYIfjPWIxa_KCgo3jH6B8_SQ130_assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP939433.RAmYGiDuBotZpQckKjVB7qYIfjPWIxa_KCgo3jH6B8_SQ130_provenance.
- NP939432.RAO78Q4vZ1_L6G0XNYmdXa21_4rzNt1DZ_3SvIzopi89M130_assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP939432.RAO78Q4vZ1_L6G0XNYmdXa21_4rzNt1DZ_3SvIzopi89M130_provenance.
- NP939434.RAxZ4PEXlBMZB2k5rmaU4fDojkd4U2ySdzAd_Yf9ROGaU130_assertion description "[dc-CISH is a promising alternative to FISH in HER2 testing, and the single-institute incidence of HER2 amplification in breast cancer in Taiwan is 21.2%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP939434.RAxZ4PEXlBMZB2k5rmaU4fDojkd4U2ySdzAd_Yf9ROGaU130_provenance.